Journal of Hepatology最新文献

{"title":"Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC)","authors":"Nina Rodriguez, Cecilia Katzenstein, Susanna O’Kula, Tatyana Kushner","doi":"10.1016/j.jhep.2025.05.018","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.018","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>All authors and collaborators contributed to this report’s conception. Material preparation and data collection were performed by NR and CK, with additional contextual insights from SO. The first draft of the manuscript was co-written by NR and CK. TK provided supervision, resources, and led the editing process. TK, SH, and LF provided details on clinical decision making. All authors provided revisions on previous versions. All authors read and approved the final manuscript.</section></section><section><section><h2>Financial support</h2>TK is supported by the NIH NHLBI K23HL16163486 award. The other authors received no financial support to produce this report.</section></section><section><section><h2>Declaration of Competing Interest</h2>TK has research support from Gilead. TK has advisory roles in Gilead, Abbvie, Ipsen, Eiger, Mirum, and GSK. The other authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"28 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sympathetic activation of adipose tissue lipolysis underlies overnutrition-induced metabolic dysfunction","authors":"Panu K. Luukkonen","doi":"10.1016/j.jhep.2025.05.021","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.021","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of intrahepatic lipids (primarily triglycerides) along with at least one cardiometabolic risk factor.¹ Fatty acids in hepatic triglycerides may originate from several sources, such as adipose tissue lipolysis, hepatic <em>de novo</em> lipogenesis, and spillover of fatty acids during postprandial chylomicron metabolism.¹^,² Among these, adipose tissue is the predominant contributor, accounting for</section></section><section><section><h2>Objectives, methods, and findings</h2>The primary objective of the study by Sakamoto <em>et al.</em> was to elucidate the role of SNS activity in the development of insulin resistance and metabolic dysfunction in the context of overnutrition and obesity. To this end, the authors first assessed the effects of overnutrition on SNS activation and subsequently investigated its mechanistic contribution using a novel murine model with inducible and peripherally restricted deletion of tyrosine hydroxylase (TH_del), the rate-limiting enzyme in</section></section><section><section><h2>Significance of findings</h2>The study by Sakamoto <em>et al.</em> provides novel insights into the contribution of SNS activation to overnutrition-induced metabolic dysfunction, insulin resistance, and MASLD. The authors demonstrate that overnutrition triggers an early increase in SNS activity, which coincides with impaired antilipolytic insulin action in adipose tissue despite preserved insulin signaling at the cellular level. This dissociation underscores the importance of functional, rather than solely molecular, assessments of</section></section><section><section><h2>Financial support</h2>Dr. Luukkonen was supported by the Academy of Finland (350545), the Sigrid Jusélius Foundation, the Novo Nordisk Foundation (NNF22OC0074397), the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Liv och Hälsa Foundation, the Finnish Government Research Funding, the Wilhelm and Else Stockmann Foundation and the Early Career Investigator fund of the University of Helsinki.</section></section><section><section><h2>Declaration of AI-assisted technologies in the writing process</h2>During the preparation of this work the author used GPT-4 in order to proofread the manuscript. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the publication.</section></section><section><section><h2>Conflict of interest</h2>The author of this study declares that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"9 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Editor’s Desk…","authors":"Philip Newsome,&nbsp;Frank Tacke,&nbsp;Heiner Wedemeyer,&nbsp;Lorenza Rimassa,&nbsp;Annalisa Berzigotti,&nbsp;Tom H. Karlsen,&nbsp;Vlad Ratziu","doi":"10.1016/j.jhep.2025.05.015","DOIUrl":"10.1016/j.jhep.2025.05.015","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Pages 1-4"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144296797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The GENIAL consortium brings together partners with unique expertise in clinical hepatology, as well as artificial intelligence to improve diagnosis of ALD-HC","authors":"","doi":"10.1016/S0168-8278(25)02220-2","DOIUrl":"10.1016/S0168-8278(25)02220-2","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Page v"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EASL Guidelines app is your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Download it now!","authors":"","doi":"10.1016/S0168-8278(25)02217-2","DOIUrl":"10.1016/S0168-8278(25)02217-2","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Page ii"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysphagia associated with portal hypertension and hepatocellular carcinoma, singular coincidence or hidden pathway?","authors":"Tristan Goncalves ,&nbsp;Léa Letrillart ,&nbsp;Claire Carlier ,&nbsp;Camille Boulagnon-Rombi ,&nbsp;Elia Gigante","doi":"10.1016/j.jhep.2025.03.011","DOIUrl":"10.1016/j.jhep.2025.03.011","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Pages e13-e15"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144296958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discover the EASL DeepDive, a free educational webinar series offering an in-depth exploration of specific topics in hepatology and liver research","authors":"","doi":"10.1016/S0168-8278(25)02219-6","DOIUrl":"10.1016/S0168-8278(25)02219-6","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Page iv"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JHEP at a glance (July 2025)","authors":"","doi":"10.1016/S0168-8278(25)02225-1","DOIUrl":"10.1016/S0168-8278(25)02225-1","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Pages e1-e12"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144296798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Join the community and become an EASL member today!","authors":"","doi":"10.1016/S0168-8278(25)02218-4","DOIUrl":"10.1016/S0168-8278(25)02218-4","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 1","pages":"Page iii"},"PeriodicalIF":26.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification","authors":"Federica Tavaglione, Luis Antonio Díaz, Veeral Ajmera, Egbert Madamba, Seema Singh, Ricki Bettencourt, Lisa Richards, Rohit Loomba","doi":"10.1016/j.jhep.2025.05.030","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.030","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;The 2023 subclassification of steatotic liver disease (SLD) relies on self-reported alcohol use, which lacks diagnostic precision in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity and specificity. In this study, we primarily aimed to estimate the prevalence of underreported alcohol use, identify its independent predictors, and enhance SLD subclassification using PEth in a large, population-based cohort of individuals with overweight/obesity and SLD in the United States.&lt;h3&gt;Methods&lt;/h3&gt;This is a cross-sectional analysis of a prospective study including 391 community-dwelling adults with overweight/obesity and SLD, as defined by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) ≥5%, residing in Southern California. Participants underwent a standardized clinical research visit, including MRI assessment and PEth testing.&lt;h3&gt;Results&lt;/h3&gt;In this cohort, the mean (SD) age and body mass index (BMI) were 51 (13) years and 33 (6) kg/m&lt;sup&gt;2&lt;/sup&gt;, respectively. As PEth levels increased, insulin resistance and hemoglobin A1c decreased, while blood pressure and high-density lipoprotein cholesterol (HDL-C) increased. 15.9% (95% CI: 12.2%–19.5%) of individuals with SLD underreported their alcohol consumption. Male gender, absence of type 2 diabetes, and White race were the strongest independent factors associated with alcohol underreporting in this population. The use of PEth in addition to self-reported alcohol use resulted in a 4-fold and 3-fold increase in MetALD and ALD diagnoses, respectively. Male gender, aspartate aminotransferase, mean corpuscular volume, HDL-C, and MRI-PDFF were the strongest independent factors associated with higher PEth. PEth and self-reported alcohol use showed a moderate positive correlation, while the agreement was low.&lt;h3&gt;Conclusions&lt;/h3&gt;PEth may objectively quantify alcohol use and help identify SLD subcategories alongside clinical history, mitigating diagnostic misclassification.&lt;h3&gt;Impact and implications&lt;/h3&gt;The current subclassification of steatotic liver disease (SLD) relies on self-reported alcohol use, which is frequently limited by patient underreporting, potentially leading to diagnostic misclassification. In this study of 391 community-dwelling adults with overweight/obesity and SLD assessed by advanced MRI methods, we found that 15.9% (95% CI: 12.2%–19.5%) of individuals with SLD underreported alcohol use based on their phosphatidylethanol (PEth) levels. Male gender, absence of type 2 diabetes, and White race were the strongest independent factors associated with alcohol underreporting in this population. The incorporation of PEth alongside self-reported alcohol use resulted in a 4-fold increase in MetALD diagnoses and a 3-fold increase in ALD diagnoses. These findings support the clinical utility of PEth as a direct, quantitative, objective alcohol biomarker which may help clinicians ide","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"35 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}